Toward precision psychiatry: theoretical implications of bimodal response patterns to vasopressin V1b receptor inhibition in depression
These findings support the hypothesis that nelivaptan effectively reduces depressive symptoms specifically in a subset of MDD patients, potentially identifiable by underlying HPA axis dysfunction. The confirmation of this hypothesis requires further studies integrating measures of HPA axis activity alongside response to nelivaptan treatment, facilitating precision psychiatry approaches for depression.
Authors
- Guy Griebel (ORCID: https://orcid.org/0000-0002-6052-9438)
- Lars Arvastson
- Christine zu Eulenburg (ORCID: https://orcid.org/0000-0001-9365-5548)
- Bertram Müller‐Myhsok (ORCID: https://orcid.org/0000-0002-0719-101X)
- D. Gehrlach
- Hans Eriksson (ORCID: https://orcid.org/0000-0002-1799-289X)
- C. Strote
- Marius Myhsok
Institutions
- Universität Hamburg (DE)
- Sanofi (France) (FR)
- LMU Klinikum (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- HolsboerMaschmeyer NeuroChemie (Germany) (DE)
- Max Planck Institute of Psychiatry (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Frontiers in Psychiatry
- Published
- 2025-10-16
- DOI
- https://doi.org/10.3389/fpsyt.2025.1645225
- Primary Topic
- Neuroendocrine regulation and behavior
- Type
- article
- Field-Weighted Citation Impact
- 0.00